These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10980817)

  • 21. Update on digoxin and other oral positive inotropic agents for chronic heart failure.
    Reddy S; Benatar D; Gheorghiade M
    Curr Opin Cardiol; 1997 May; 12(3):233-41. PubMed ID: 9243080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of Chinese-made vesnarinone on experimental heart failure of dog].
    Du J; Yang Z
    Hua Xi Yi Ke Da Xue Xue Bao; 1992 Jun; 23(2):178-80. PubMed ID: 1452153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flosequinan.
    Massie BM; Shah NB; Pitt B; Packer M
    Am Heart J; 1996 Jul; 132(1 Pt 1):130-6. PubMed ID: 8701855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies.
    Reis SE; Holubkov R; Young JB; White BG; Cohn JN; Feldman AM
    J Am Coll Cardiol; 2000 Aug; 36(2):529-33. PubMed ID: 10933368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tailored treatment for heart failure.
    Shibata M; Perez de Arenaza D
    Lancet; 2000 Aug; 356(9230):686. PubMed ID: 10968472
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial.
    Deswal A; Petersen NJ; Feldman AM; White BG; Mann DL
    Chest; 2001 Aug; 120(2):453-9. PubMed ID: 11502643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).
    Deswal A; Petersen NJ; Feldman AM; Young JB; White BG; Mann DL
    Circulation; 2001 Apr; 103(16):2055-9. PubMed ID: 11319194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design of phase II trials in congestive heart failure.
    DeMets DL
    Am Heart J; 2000 Apr; 139(4):S207-10. PubMed ID: 10740134
    [No Abstract]   [Full Text] [Related]  

  • 29. Digoxin may reduce the mortality rates in patients with congestive heart failure.
    Wang L; Song S
    Med Hypotheses; 2005; 64(1):124-6. PubMed ID: 15533628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential response to vesnarinone by cardiac fibroblasts isolated from normal and aortic regurgitant hearts.
    Ross JS; Goldfine SM; Herrold EM; Borer JS
    Am J Ther; 1998 Nov; 5(6):369-75. PubMed ID: 10099079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The best of times, the worst of times: the wealth and poverty of heart failure pharmacotherapies: is there a role for vesnarinone?
    Young JB
    Drug Saf; 2004; 27 Suppl 1():3 p following table of contents. PubMed ID: 15293847
    [No Abstract]   [Full Text] [Related]  

  • 32. [Efficacy and problems of cardiotonic agents viewed from physiopathology of chronic congestive heart failure].
    Asanoi H; Inoue H
    Nihon Naika Gakkai Zasshi; 1995 Sep; 84(9):1465-9. PubMed ID: 8537751
    [No Abstract]   [Full Text] [Related]  

  • 33. [Study of heart failure. Is phytotherapy effective?].
    MMW Fortschr Med; 2001 Jun; 143(25):59. PubMed ID: 11469004
    [No Abstract]   [Full Text] [Related]  

  • 34. Is there a role for positive inotropic agents in congestive heart failure: focus on mortality.
    Amidon TM; Parmley WW
    Clin Cardiol; 1994 Dec; 17(12):641-7. PubMed ID: 7867235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Digitalis for treatment of heart failure].
    Hirai T; Asanoi H
    Nihon Rinsho; 2007 May; 65 Suppl 5():19-24. PubMed ID: 17571360
    [No Abstract]   [Full Text] [Related]  

  • 36. Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial.
    Böhm M; Link A; Cai D; Nieminen MS; Filippatos GS; Salem R; Cohen Solal A; Huang B; Padley RJ; Kivikko M; Mebazaa A
    Crit Care Med; 2011 May; 39(5):940-4. PubMed ID: 21283007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should we revise our approach to 'optimal medical therapy'? The case of chronic heart failure.
    Tavazzi L; Maggioni AP; Borer JS
    Eur Heart J; 2013 Sep; 34(36):2792-4. PubMed ID: 23892200
    [No Abstract]   [Full Text] [Related]  

  • 38. Vesnarinone restores contractility and calcium handling in early endotoxemia.
    Takeuchi K; del Nido PJ; Poutias DN; Cowan DB; Munakata M; McGowan FX
    Circulation; 2000 Nov; 102(19 Suppl 3):III365-9. PubMed ID: 11082415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Challenge for the general practitioner. Sufficient therapy for heart failure].
    Füessl HS
    MMW Fortschr Med; 2000 Nov; 142(46):4-8. PubMed ID: 11132311
    [No Abstract]   [Full Text] [Related]  

  • 40. Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heart.
    Kitakaze M; Minamino T; Funaya H; Node K; Shinozaki Y; Mori H; Hori M
    Circulation; 1997 Apr; 95(8):2108-14. PubMed ID: 9133521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.